Exercise of Warrants and Total Voting Rights

RNS Number : 9565F

N4 Pharma PLC

23 May 2017

 

23 May 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Exercise of Warrants and Total Voting Rights

The Company announces that it has received exercise notices for the exercise of, in aggregate, 375,000 warrants over ordinary shares of 0.4p each at an exercise price of 8 pence per warrant ("New Ordinary Shares"). Application has been made for admission of 375,000 New Ordinary Shares to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on 26 May 2017.

Following Admission, there will be a total of 72,089,285 ordinary shares in issue. Shareholders should use the figure of 72,089,285 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure and Transparency Rules.

Enquiries:

N4 Pharma CEO, Nigel Theobald	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: [phone]
Beaufort Securities Elliot Hance	Tel: [phone]
Alma PR Josh Royston Robyn Fisher	Tel: [phone] Tel: [phone]

About N4 Pharma

N4 Pharma was formed in 2014 by Nigel Theobald, the former Chief Executive of AIM quoted Oxford Pharmascience Group plc. It is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

 

END

 

 

MSCDMGZKRFGGNZG